Ruchi Gupta, MD, MPH, attended the 2025 AAAAI/WAO Joint Congress and spent the week reflecting on the numerous advancements presented. She highlights exciting developments in the treatment of chronic spontaneous urticaria, emphasizing the benefits of initiating biologic therapy like omalizumab earlier for improved patient outcomes, with promising trials also underway for dupilumab.
Additionally, Dr Gupta discusses progress in food allergy treatments, including the approval of peanut oral allergen powder for peanut allergy and emerging data on omalizumab for multi-food allergies. She also notes the availability of epinephrine nasal spray and the anticipated release of sublingual epinephrine, marking significant strides in patient care options.